Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7

A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of hematology 1996-05, Vol.72 (5), p.337-340
Hauptverfasser: HASHINO, S, IMAMURA, M, TANAKA, J, KOBAYASHI, S, MUSASHI, M, KASAI, M, ASAKA, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 340
container_issue 5
container_start_page 337
container_title Annals of hematology
container_volume 72
creator HASHINO, S
IMAMURA, M
TANAKA, J
KOBAYASHI, S
MUSASHI, M
KASAI, M
ASAKA, M
description A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After 2 years of the therapy, monosomy 7 was detected during cytogenetic analysis of his bone marrow, which evolved during a period of 5 months into acute myeloblastic leukemia. An in vitro proliferation assay of cytokine responses showed that leukemic blasts were sensitive only to G-CSF, and not to EPO or IL-6. Although allogeneic bone marrow transplantation from an HLA-matched unrelated donor was carried out in the non-remission stage, the patient died of systemic fungal infection on day 25, without any evidence of hematological engraftment. As long-term use of cytokines and immunomo-suppressants in patients with severe aplastic anemia may induce or hasten the onset of a malignant transformation, careful attention must be paid to clonal evolution. Due to the poor prognosis of secondary myelodysplasia and leukemia, allogeneic bone marrow transplantation for such patients must be carried out early in the course of the disease.
doi_str_mv 10.1007/s002770050183
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78088232</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78088232</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-6bdc262e69e89f2a3613be8a3494f27dac31fe76d43bb451be2e075345bb5833</originalsourceid><addsrcrecordid>eNpVkEtLxDAUhYMo4zi6dClkIe6qeTbpUsQXDLiZjauSZG4x2jRj0irz761OGfBuzuJ8HC4fQueUXFNC1E0mhClFiCRU8wM0p4KzgkgtDtGcVLwq5HjH6CTnd0Io04LN0EyXQipRzdHrKpkuNzEF0_vY4djgDF-QAJtNa3LvHTYdBG-w7_qIjRt6wGELbbRT3cLw8Qd8-_4Nh9jFHMMWq1N01Jg2w9mUC7R6uF_dPRXLl8fnu9tl4ThVfVHatWMlg7ICXTXM8JJyC9pwUYmGqbUZsQZUuRbcWiGpBQZESS6ktVJzvkBXu9lNip8D5L4OPjto2_HtOORaaaI142wEix3oUsw5QVNvkg8mbWtK6l-T9T-TI38xDQ82wHpPT-rG_nLqTXambUaPzuc9xkmldSn5D56Je6s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78088232</pqid></control><display><type>article</type><title>Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>HASHINO, S ; IMAMURA, M ; TANAKA, J ; KOBAYASHI, S ; MUSASHI, M ; KASAI, M ; ASAKA, M</creator><creatorcontrib>HASHINO, S ; IMAMURA, M ; TANAKA, J ; KOBAYASHI, S ; MUSASHI, M ; KASAI, M ; ASAKA, M</creatorcontrib><description>A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After 2 years of the therapy, monosomy 7 was detected during cytogenetic analysis of his bone marrow, which evolved during a period of 5 months into acute myeloblastic leukemia. An in vitro proliferation assay of cytokine responses showed that leukemic blasts were sensitive only to G-CSF, and not to EPO or IL-6. Although allogeneic bone marrow transplantation from an HLA-matched unrelated donor was carried out in the non-remission stage, the patient died of systemic fungal infection on day 25, without any evidence of hematological engraftment. As long-term use of cytokines and immunomo-suppressants in patients with severe aplastic anemia may induce or hasten the onset of a malignant transformation, careful attention must be paid to clonal evolution. Due to the poor prognosis of secondary myelodysplasia and leukemia, allogeneic bone marrow transplantation for such patients must be carried out early in the course of the disease.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s002770050183</identifier><identifier>PMID: 8645749</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Anemia, Aplastic - complications ; Anemia, Aplastic - therapy ; Anemias. Hemoglobinopathies ; Antilymphocyte Serum - therapeutic use ; Biological and medical sciences ; Bone Marrow Transplantation ; Chromosomes, Human, Pair 7 ; Cyclosporine - therapeutic use ; Diseases of red blood cells ; Erythropoietin - therapeutic use ; Granulocyte Colony-Stimulating Factor - therapeutic use ; Hematologic and hematopoietic diseases ; Humans ; Interleukin-6 - therapeutic use ; Leukemia, Myeloid, Acute - etiology ; Leukemia, Myeloid, Acute - genetics ; Male ; Medical sciences ; Monosomy</subject><ispartof>Annals of hematology, 1996-05, Vol.72 (5), p.337-340</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-6bdc262e69e89f2a3613be8a3494f27dac31fe76d43bb451be2e075345bb5833</citedby><cites>FETCH-LOGICAL-c317t-6bdc262e69e89f2a3613be8a3494f27dac31fe76d43bb451be2e075345bb5833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3098865$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8645749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HASHINO, S</creatorcontrib><creatorcontrib>IMAMURA, M</creatorcontrib><creatorcontrib>TANAKA, J</creatorcontrib><creatorcontrib>KOBAYASHI, S</creatorcontrib><creatorcontrib>MUSASHI, M</creatorcontrib><creatorcontrib>KASAI, M</creatorcontrib><creatorcontrib>ASAKA, M</creatorcontrib><title>Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After 2 years of the therapy, monosomy 7 was detected during cytogenetic analysis of his bone marrow, which evolved during a period of 5 months into acute myeloblastic leukemia. An in vitro proliferation assay of cytokine responses showed that leukemic blasts were sensitive only to G-CSF, and not to EPO or IL-6. Although allogeneic bone marrow transplantation from an HLA-matched unrelated donor was carried out in the non-remission stage, the patient died of systemic fungal infection on day 25, without any evidence of hematological engraftment. As long-term use of cytokines and immunomo-suppressants in patients with severe aplastic anemia may induce or hasten the onset of a malignant transformation, careful attention must be paid to clonal evolution. Due to the poor prognosis of secondary myelodysplasia and leukemia, allogeneic bone marrow transplantation for such patients must be carried out early in the course of the disease.</description><subject>Adult</subject><subject>Anemia, Aplastic - complications</subject><subject>Anemia, Aplastic - therapy</subject><subject>Anemias. Hemoglobinopathies</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation</subject><subject>Chromosomes, Human, Pair 7</subject><subject>Cyclosporine - therapeutic use</subject><subject>Diseases of red blood cells</subject><subject>Erythropoietin - therapeutic use</subject><subject>Granulocyte Colony-Stimulating Factor - therapeutic use</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Interleukin-6 - therapeutic use</subject><subject>Leukemia, Myeloid, Acute - etiology</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Monosomy</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkEtLxDAUhYMo4zi6dClkIe6qeTbpUsQXDLiZjauSZG4x2jRj0irz761OGfBuzuJ8HC4fQueUXFNC1E0mhClFiCRU8wM0p4KzgkgtDtGcVLwq5HjH6CTnd0Io04LN0EyXQipRzdHrKpkuNzEF0_vY4djgDF-QAJtNa3LvHTYdBG-w7_qIjRt6wGELbbRT3cLw8Qd8-_4Nh9jFHMMWq1N01Jg2w9mUC7R6uF_dPRXLl8fnu9tl4ThVfVHatWMlg7ICXTXM8JJyC9pwUYmGqbUZsQZUuRbcWiGpBQZESS6ktVJzvkBXu9lNip8D5L4OPjto2_HtOORaaaI142wEix3oUsw5QVNvkg8mbWtK6l-T9T-TI38xDQ82wHpPT-rG_nLqTXambUaPzuc9xkmldSn5D56Je6s</recordid><startdate>19960501</startdate><enddate>19960501</enddate><creator>HASHINO, S</creator><creator>IMAMURA, M</creator><creator>TANAKA, J</creator><creator>KOBAYASHI, S</creator><creator>MUSASHI, M</creator><creator>KASAI, M</creator><creator>ASAKA, M</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960501</creationdate><title>Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7</title><author>HASHINO, S ; IMAMURA, M ; TANAKA, J ; KOBAYASHI, S ; MUSASHI, M ; KASAI, M ; ASAKA, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-6bdc262e69e89f2a3613be8a3494f27dac31fe76d43bb451be2e075345bb5833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Anemia, Aplastic - complications</topic><topic>Anemia, Aplastic - therapy</topic><topic>Anemias. Hemoglobinopathies</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation</topic><topic>Chromosomes, Human, Pair 7</topic><topic>Cyclosporine - therapeutic use</topic><topic>Diseases of red blood cells</topic><topic>Erythropoietin - therapeutic use</topic><topic>Granulocyte Colony-Stimulating Factor - therapeutic use</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Interleukin-6 - therapeutic use</topic><topic>Leukemia, Myeloid, Acute - etiology</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Monosomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HASHINO, S</creatorcontrib><creatorcontrib>IMAMURA, M</creatorcontrib><creatorcontrib>TANAKA, J</creatorcontrib><creatorcontrib>KOBAYASHI, S</creatorcontrib><creatorcontrib>MUSASHI, M</creatorcontrib><creatorcontrib>KASAI, M</creatorcontrib><creatorcontrib>ASAKA, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HASHINO, S</au><au>IMAMURA, M</au><au>TANAKA, J</au><au>KOBAYASHI, S</au><au>MUSASHI, M</au><au>KASAI, M</au><au>ASAKA, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>1996-05-01</date><risdate>1996</risdate><volume>72</volume><issue>5</issue><spage>337</spage><epage>340</epage><pages>337-340</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>A cytogenetically normal man with severe aplastic anemia was treated with granulocyte colonystimulating factor (G-CSF), erythropoietin (EPO), cyclosporin A, anti-thymocyte globulin, and interleukin-6 (IL-6), which resulted in a gradual improvement in his neutrophil count and hemoglobin level. After 2 years of the therapy, monosomy 7 was detected during cytogenetic analysis of his bone marrow, which evolved during a period of 5 months into acute myeloblastic leukemia. An in vitro proliferation assay of cytokine responses showed that leukemic blasts were sensitive only to G-CSF, and not to EPO or IL-6. Although allogeneic bone marrow transplantation from an HLA-matched unrelated donor was carried out in the non-remission stage, the patient died of systemic fungal infection on day 25, without any evidence of hematological engraftment. As long-term use of cytokines and immunomo-suppressants in patients with severe aplastic anemia may induce or hasten the onset of a malignant transformation, careful attention must be paid to clonal evolution. Due to the poor prognosis of secondary myelodysplasia and leukemia, allogeneic bone marrow transplantation for such patients must be carried out early in the course of the disease.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>8645749</pmid><doi>10.1007/s002770050183</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0939-5555
ispartof Annals of hematology, 1996-05, Vol.72 (5), p.337-340
issn 0939-5555
1432-0584
language eng
recordid cdi_proquest_miscellaneous_78088232
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Adult
Anemia, Aplastic - complications
Anemia, Aplastic - therapy
Anemias. Hemoglobinopathies
Antilymphocyte Serum - therapeutic use
Biological and medical sciences
Bone Marrow Transplantation
Chromosomes, Human, Pair 7
Cyclosporine - therapeutic use
Diseases of red blood cells
Erythropoietin - therapeutic use
Granulocyte Colony-Stimulating Factor - therapeutic use
Hematologic and hematopoietic diseases
Humans
Interleukin-6 - therapeutic use
Leukemia, Myeloid, Acute - etiology
Leukemia, Myeloid, Acute - genetics
Male
Medical sciences
Monosomy
title Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T13%3A05%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transformation%20of%20severe%20aplastic%20anemia%20into%20acute%20myeloblastic%20leukemia%20with%20monosomy%207&rft.jtitle=Annals%20of%20hematology&rft.au=HASHINO,%20S&rft.date=1996-05-01&rft.volume=72&rft.issue=5&rft.spage=337&rft.epage=340&rft.pages=337-340&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s002770050183&rft_dat=%3Cproquest_cross%3E78088232%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78088232&rft_id=info:pmid/8645749&rfr_iscdi=true